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94(31.3%), 26 mm (37.5%), and 29 mm (31.3%) for the
balloon-expanding valves. Two self-expanding
valves were implanted in 1 patient (2.3%). The
mean sheath size was 18.8  2.1-F.
After the procedure, the mean aortic valve gradient
was reduced from 46.8  13.0 mm Hg at baseline to
9.3  4.0 mm Hg (D37.4  12.3 mm Hg; p < 0.001 for
paired echocardiograms), whereas moderate/severe
paravalvular regurgitation and new permanent pace-
maker implantation were observed in 12.2% and
20.5% of the patients, respectively. The median
length of intensive care unit and hospital stays was
relatively short (2.0 [IQR: 1.0 to 4.0] days and 6.0
[IQR: 5.0 to 8.0] days, respectively). In-hospital and
30-day mortality was 4.5% and 9.1%, respectively.
The median follow-up was 503 days (IQR: 155 to
808 days), and no patient was lost to follow-up. One-
year mortality was 34.1%. One-year rates of major
adverse cardiac and cerebrovascular event and reho-
spitalization were 36.4% and 47.7%, respectively.
To our knowledge, this is the largest multicenter
report on the results of early and mid-term outcome
of TAVR in chronic dialysis patients. The 30-day
mortality of 9.1% in our study is comparable with
the 30-day mortality of 7.6% and 9.7% in the overall
population in the Transcatheter Valve Therapy Reg-
istries (Sapien THV), as well as in the FRANCE-2 reg-
istry (both Sapien and CoreValve THV), respectively
(4,5); therefore, considering the severe comorbidity
and frailty of our patients, our results further support
performing TAVR in this complex setting. In addition,
shorter intensive care unit and hospital stays would
be a great advantage for these high-risk and frail pa-
tients. Highly calciﬁed aorta (i.e., porcelain aorta) and
iliofemoral vessels are major concerns in patients
with chronic dialysis. In this study, however, neither
stroke nor major vascular complications (i.e., need
of surgical or endovascular intervention) occurred in
the TAVR group. Conversely, 1-year mortality in
our study was higher than that in the FRANCE-2
registry (34.1% vs. 24%), demonstrating the high
cardiovascular risk proﬁle in this subgroup. While a
large sample size was initially included, the relatively
limited number of dialysis patients precluded deﬁn-
itive conclusions. Our initial ﬁndings, as well as the
most appropriate therapy (i.e., TAVR or SAVR) for
severe AS patients with dialysis warrant future
investigation.
In conclusion, our preliminary experience utilizing
data from a large multicenter registry suggests in a
mid-term follow-up, favorable safety, and efﬁcacy
of TAVR in patients with severe AS and chronic
dialysis.Yohei Ohno, MD
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Trimethylamine-N-Oxide
and Heart FailureThe new study by Tang et al. (1) demonstrating an
inverse correlation of serum levels of trimethylamine-
N-oxide (TMAO) with survival in patients with heart
failure (HF) is intriguing and thought provoking.
Similar ﬁndings have been published recently by
Norwegian researchers.
In our judgment, TMAO is more likely to be a
marker than a mediator in this relationship. Fish,
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95especially deep-ocean ﬁsh, is exceptionally high in
TMAO, with a TMAO content of 1.7 g per pound or
higher. As noted previously, human TMAO exposure
resulting from ingestion of a pound of ﬁsh could
be expected to be an order of magnitude higher
than that which would result from ingestion of a
pound of carnitine-rich red meat (2). Nonetheless,
dietary ﬁsh consumption has been correlated in-
versely with the risk of HF in several prospective
cohorts, including the Physicians’ Health Study;
how ﬁsh intake correlates with survival in pre-
existing HF does not appear to have been studied.
Very likely, the long-chain omega-3 content of ﬁsh
is largely responsible for its protective efﬁcacy in
this regard.
Dietary carnitine can boost the production of
TMAO in the body, yet supplemental carnitine has
been shown to be therapeutically beneﬁcial in
patients with HF. In controlled clinical trials, carni-
tine supplementation of HF patients has been found
to improve exercise performance, increase left ven-
tricular ejection fraction, slow the increase in end-
diastolic and end-systolic volumes, and improve
clinical indexes such as edema, dyspnea, and digitalis
consumption. In 1 study of 3 years’ duration, long
enough to assess an impact on mortality, survival
was signiﬁcantly higher in those receiving carnitine
(3). Hence, it would be inappropriate to conclude
from the inverse correlation of TMAO and survival
in HF that dietary carnitine has an adverse inﬂuence
on HF.
A corollary of these considerations is that the
predictive value of TMAO in HF would likely be
compromised in individuals or groups who ingest
ample amounts of ﬁsh or who take supplemental
carnitine.
These considerations evidently do not rule out the
possibility that TMAO itself, in the high-normal
clinical range, might exert an adverse effect on the
clinical course of HF, but they do suggest that
any impact in this regard is modest compared with
the protective beneﬁts of long-chain omega-3 or of
L-carnitine. Moreover, there is reason to question
whether TMAO exerts meaningful proatherogenic
activity at the low micromolar levels observed in
human plasma (2).
Alternatively, elevated serum TMAO may serve as
a marker for other dietary or metabolic factors that
are the true mediators of risk. Red meat is the richest
natural dietary source of carnitine and hence tends to
raise serum TMAO levels. In the Physicians’ Health
Study, red meat consumption correlated positively
with the risk of HF, with or without a previous
myocardial infarction. A recent Swedish studycorrelated increased consumption of processed red
meat, but not unprocessed red meat, with an
increased risk of HF. Dietary choline also raises TMAO
levels; red meat is a meaningful dietary source of
choline as are dairy products and eggs. In the pro-
spective ARIC (Atherosclerosis Risk in Communities)
study, consumption of high-fat dairy products and
eggs correlated with an increased risk of HF. Hence,
increased serum TMAO may be serving as a marker for
dietary choices that by independent mechanisms
tend to promote HF. In this regard, among HF pa-
tients enrolled in a clinical trial evaluating sodium
restriction, dietary saturated fat consumption was
shown to correlate positively with 1-year mortality,
whereas dietary consumption of polyunsaturates
correlated inversely (4). Also, plasma phospholipid
levels of saturated fats or of palmitic acid speciﬁcally
have been reported to correlate with the risk of HF in
ARIC and the Physicians’ Health Study.
In the Tang et al. (1) study, TMAO correlated
inversely with the estimated glomerular ﬁltration
rate; because TMAO is found in urine, this likely
reﬂects a role for renal clearance in the regulation
of plasma TMAO levels. However, the authors show
that TMAO retains predictive value after statistical
correction of the estimated glomerular ﬁltration rate,
so TMAO is not serving solely as a marker for this
parameter.
Finally, as the authors note, increased serum
TMAO might conceivably be a marker for the presence
of gastrointestinal ﬂora that work in independent
ways to worsen prognosis in HF.
Curiously, TMAO, like 4-phenylbutyrate or taur-
odeoxycholate, can act as a small-molecule chemical
chaperone that suppresses endoplasmic reticulum
(ER) stress. This is thought to explain the favorable
impact of TMAO administration in rodent models of
asthma, diabetic neuropathy, and cataract. More-
over, ER stress appears to be an exacerbating factor
in HF, linked to an increased risk of apoptosis of
cardiomyocytes; hence, it has been suggested that
agents that counteract ER stress may have a role in
the management of HF. Indeed, the orphan drug
4-phenylbutyrate was protective in a rodent model
of pressure-overload cardiac hypertrophy. Could
high intakes of TMAO actually play a protective role
in HF? (This is not necessarily inconsistent with the
ﬁndings of Tang et al. (1) because the low micro-
molar physiological concentrations of TMAO would
be expected to have little meaningful chaperone
activity.) This possibility could be evaluated in
rodent studies.
Considerable evidence also points to ER stress
as a driver of atherogenesis, foam cell formation,
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phages and smooth muscle cells. Indeed, both
4-phenylbutyrate and taurodeoxycholate are re-
ported to exert antiatherosclerotic activity in rodent
studies and to suppress induction of CD36 and
scavenger receptor A in macrophages. In notable
contrast, TMAO has been found to have a proa-
therogenic effect in mice and to up-regulate CD36
and scavenger receptor A expression in macrophages
(5). Although it is quite conceivable that TMAO has
some idiosyncratic adverse countervailing effect
on foam cells that outweighs the beneﬁt of its
inhibitory inﬂuence on ER stress, it should be noted
that only 1 research group to date has reported a
proatherogenic role for TMAO; this observation
needs independent conﬁrmation before it can be
accepted as established fact.*Mark F. McCarty, BA
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We thank Mr. McCarty and Dr. DiNicolantonio for
their interest and their opinions regarding our dis-
covery of a previously unappreciated role for the
potential involvement of a speciﬁc gut microbiota–
dependent pathway leading to higher circulating
trimethylamine N-oxide (TMAO) levels that wereassociated with a worse prognosis independent of
traditional cardiorenal indices and risk factors. We
believe that the observed associations are hypothesis
generating and call for further rigorous mechanistic
investigations. Our reported association between
elevated TMAO levels and an adverse prognosis
among subjects with heart failure was recently vali-
dated in independent cohorts of patients, including
among subjects with chronic systolic heart failure
(left ventricular ejection fraction #35%) with well-
characterized echocardiographic assessments (1),
as well as in a Norwegian cohort with similar
observations (2). There are also emerging data to
demonstrate the potential interplay between TMAO
and other neurohormonal systems that are implicated
in the pathogenesis of heart failure and other car-
diovascular diseases (3). Thus, a rapidly growing body
of evidence suggests that elevated TMAO levels are
strikingly linked to an adverse prognosis in heart
failure patients, and further studies are warranted to
determine whether the observed associations are
causal, which may point toward important potential
nutritional or other preventive efforts that might
mitigate the observed risk.
We agree that the role of dietary choices and
nutritional exposure as mechanistic underpinnings
of heart failure pathophysiology has been specu-
lated for several decades. However, unlike many
commentaries, we are very careful not to make any
unfounded speculations regarding any single di-
etary source of TMAO production as the sole culprit.
The challenge in investigations of this topic is
largely due to the difﬁculties in objective quanti-
ﬁcation in a rigorous scientiﬁc manner. Epidemio-
logical studies are limited in their precision and
accuracy to measure dietary composition. In our
own published data, systemic levels of L-carnitine,
choline, as well as betaine portend poorer long-term
prognosis when there is a concomitant increase in
circulating TMAO levels. Moreover, we recently
discovered the contributory role of g-butyrobetaine,
an intermediate metabolite of L-carnitine that is
vital to carnitine metabolism in vegetarians/vegans,
which may potentially siphon oral L-carnitine avail-
ability upstream from the gastrointestinal tract (4).
These novel observations further illustrate the
complex interplay between dietary nutrients, gut
microbial metabolism, and host homeostasis, above
and beyond a simplistic explanation to justify or
refute any therapeutic approaches. It is true that
some species of ﬁsh have a high TMAO content,
whereas many others do not. A similar situation is
observed with the content of speciﬁc molecular
